Company intelligence / Profile preview

Urovant Sciences

Irvine, California, United Statesus.sumitomo-pharma.com ↗

Ownership: Private
Employees: ~310
Development stage: Commercial

Overview

Urovant Sciences has received FDA approval for GEMTESA (vibegron) 75mg tablets for treating overactive bladder in December 2020. Their gene therapy candidate URO-902 showed positive Phase 2a results with clinically meaningful impact on OAB symptoms compared to placebo.

Therapeutic areas: Men's HealthUrologyNephrology
Modalities: Small moleculesGene therapy
Industry: Biotech

Drug pipeline

2 assets

vibegron

Commercial

Indications: Overactive bladder, Overactive bladder in men with benign prostatic hyperplasia, Abdominal pain associated with irritable bowel syndrome

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Urovant Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Urovant Sciences.

Explore the full profile